Precipio (NASDAQ:PRPO) Shares Cross Below 200-Day Moving Average of $3.16

Precipio (NASDAQ:PRPO)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.16 and traded as low as $2.08. Precipio shares last traded at $2.09, with a volume of 21,234 shares changing hands.

Separately, Maxim Group assumed coverage on Precipio in a report on Friday, November 22nd. They issued a “buy” rating and a $4.00 target price on the stock.

The company has a quick ratio of 0.60, a current ratio of 0.64 and a debt-to-equity ratio of 0.05. The firm’s 50-day moving average is $2.28 and its 200 day moving average is $3.07.

A number of large investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in Precipio during the 3rd quarter valued at about $55,000. SeaCrest Wealth Management LLC lifted its holdings in shares of Precipio by 8.7% in the third quarter. SeaCrest Wealth Management LLC now owns 59,050 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 4,750 shares in the last quarter. Morgan Stanley acquired a new stake in shares of Precipio in the second quarter valued at approximately $86,000. Finally, BlackRock Inc. acquired a new stake in shares of Precipio in the second quarter valued at approximately $47,000. Hedge funds and other institutional investors own 3.95% of the company’s stock.

About Precipio (NASDAQ:PRPO)

Precipio, Inc, a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, as well as PerkinElmer.

Featured Story: Do Tariffs Work?

Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit